(Q40609773)

English

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

scientific article published on January 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

phase I clinical trial

0 references

zoledronic acid

1 reference

based on heuristic

inferred from title

author name string

Berenson JR

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Vescio R

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Henick K

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Nishikubo C

4

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Rettig M

5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Swift RA

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Conde F

7

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Von Teichert JM

8

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

language of work or name

0 references

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

91

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

144-154

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Mechanisms of osteolytic bone destruction

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Rationale for the use of bisphosphonates in bone metastases

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Bisphosphonates: mechanisms of action and clinical use in osteoporosis--an update

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Bisphosphonates: preclinical aspects and use in osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Structure-activity relationships of various bisphosphonates

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

A dose-finding study of zoledronate in hypercalcemic cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Biochemical markers of bone metabolism: an overview

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Assessment of renal function in patients with multiple myeloma: the role of urinary proteins

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010101%2991%3A1%3C144%3A%3AAID-CNCR19%3E3.0.CO%3B2-Q

21 January 2018

Identifiers

10.1002/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO;2-Q

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40609773&oldid=1903641028"